In a striking challenge to U.S. Health and Human Services Secretary Robert F. Kennedy Jr., Governor Maura Healey of Massachusetts has called for an immediate reversal of funding cuts to the National Institutes of Health (NIH) that have resulted in the suspension of numerous clinical trials. Per a report by the Massachusetts government, these budget reductions have impeded the progress of 380 clinical trials nationwide, affecting over 74,000 patients – with 18 clinical trials and 13,000 patients in Massachusetts alone.
According to the Massachusetts government, in an October meeting, Secretary Kennedy told Governor Healey that budget cuts had not disrupted clinical trials or affected patients, a claim Healey now disputes. “You asked for proof that your actions were halting the development of lifesaving cures and treatments, and hurting patients and their families. Now you have it,” Healey wrote to Kennedy. Healey cited a JAMA Internal Medicine report showing the significant impact of NIH funding cuts on research.
Healey emphasized the impact of halting medical studies on critical health issues, including colorectal cancer, strokes, and pregnancy complications. Massachusetts, a leader in education, medicine, and life sciences, contributes over $155 billion to the national economy and employs one in ten U.S. research and development workers. The state has historically played a key role in major medical discoveries, including COVID-19 vaccines.
To address what she sees as an attack on scientific research, Governor Healey launched the DRIVE Initiative (Discovery, Research, and Innovation for a Vibrant Economy). The program seeks to sustain Massachusetts’ role in medical innovation and support jobs and the state’s economy. The state recently secured favorable rulings: a U.S. Court of Appeals upheld a lower court decision blocking the Trump Administration from capping indirect research costs at 15%, and an agreement resolved delays in NIH grant applications. Healey, however, says these do not fix the halted clinical trials.
The impasse affects thousands of patients awaiting treatments and has wide implications for U.S. medical research and the economy. The disagreement between Governor Healey and Secretary Kennedy highlights a critical debate over federal research funding and its impact on public health and state economies.
